DLP-201

Ainos continues its strategic transition away from marketing COVID test kits and further advances commercialization of its VELDONA® and VOC POCT technologies Strategic pivot is underpinned by Ainos' diversified product pipeline SAN DIEGO, CA / ACCESSWIRE / May 12, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the first quarter ended March 31, 2023. Chun-Hsien Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "The first quarter of 2023 marks the beginning of a new chapter for Ainos. As our VOC POCT and VELDONA® technologies progress towards commercialization and COVID-19 becomes endemic, we are pivoting the primary focus of our business away from COVID-19. This strategic shift comes after years of clinical trials and development for our product pipeline, and lays a solid foundation for Ainos' continued long-term growth. Past sales of our COVID-19 test kits have helped us establish key infrastructure and partnerships that will support this transition and the success of our upcoming product offerings." "During the first quarter, we made significant progress in the commercialization of our VELDONA® low-dose oral interferon-alpha ("IFNα") formulation, especially in regard to its applications for animal health. We signed an agreement with a Taiwanese pharmaceutical biotech company which granted them exclusive distribution rights for our VELDONA® animal health supplements in Taiwan, marking our entry into the multi-billion-dollar veterinary health market. Meanwhile, our efforts in developing VELDONA® drug candidates for the treatment of various human disease applications continue to progress. In addition, our lead VOC POCT testing candidate, the AI Nose platform-powered Ainos Flora, is currently undergoing clinical trials and is on track to reach commercialization by the end of 2023." "We currently operate primarily in the Taiwan market, which, in contrast to the United States, saw its COVID-19 peak occur last year. This difference in timing has allowed us to make the transition to a commercial endemic market later than our American peers while continuing to execute our long-term growth strategy. Our achievements thus far have set the stage for a successful transition into our next product cycle, and I am both proud of our progress to date and eager to see where our innovative spirit takes us in the future." Hui-Lan Wu, Chief Financial Officer of Ainos, commented, "In the first quarter of 2023, we recorded total revenues of US$49,164. We strengthened our financial position through two convertible note purchase agreements in a principal amount of US$3 million. In combination with our prudent financial management, reflected by only a small year-over-year increase in cash-based operating expenses, we have created a solid foundation from which we can continue the development and monetization of our product pipeline." First Quarter 2023 Financial Results Revenues Revenues were US$49,164 in the first quarter of 2023, compared to US$87,200 in the same period of 2022, reflecting a slowdown of COVID-19 infections in Taiwan. Cost of Revenues Cost of revenues was US$100,848 in the first quarter of 2023, compared with US$41,078 in the same period of 2022. The change was primarily attributable to the one-time inventory provision of $42,826 and unallocated manufacturing overhead of $22,602. Gross Profit In the first quarter of 2023, gross profit was negative US$51,684 compared with a positive gross profit of US$46,122 a year ago, driven by a shift in the Company's revenue mix, increased unallocated manufacturing overhead, and a one-time inventory charge. Gross profit excluding unallocated overhead and inventory provision was $13,744 in the first quarter of 2023. Total Operating Expenses Total operating expenses were US$2,461,348 in the first quarter of 2023 compared with US$2,129,184 in the same period of 2022. The change was mainly attributable to depreciation and increased staffing and share-based compensation. Operating expenses, excluding depreciation and amortization expenses and share-based compensation, were US$1,059,894 in the first quarter of 2023 as compared with US$972,746 a year ago. R&D expenses were US$1,698,883 in the first quarter of 2023 compared with US$1,577,454 a year ago. When excluding share-based compensation, depreciation and amortization expenses, R&D expenses were US$503,899, compared with US$441,241 over the same period. SG&A expenses were US$762,465 compared with US$551,730 in the same period of 2022. When excluding share-based compensation, depreciation and amortization expenses, SG&A expenses were US$555,995, compared with US$531,505 over the same period. Net Loss Net loss attributable to common stock shareholders was US$2,520,475 in the first quarter of 2023, compared with US$2,099,895 in the same period of 2022. Balance Sheet As of March 31, 2023, the Company had cash and cash equivalents of US$1,146,132 compared with US$1,853,362 as of December 31, 2022. Recent Developments On January 23, 2023, the Company announced that it had signed a Memorandum of Understanding with Taiwanese animal drug manufacturer Tah-An Chemical & Pharmaceutical Co., Ltd. to jointly explore the feasibility of manufacturing an animal investigational new drug based on the VELDONA® formulation. On March 13, 2023, the Company announced that it had entered into two convertible note purchase agreements, under which the Company issued and sold two convertible promissory notes in a principal amount of US$3 million to certain investors. On March 14, 2023 the Company announced that it had signed a Memorandum of Understanding with Merdury Biopharmaceutical Corp., a Taipei Exchange Emerging Stock Board listed company, to jointly explore and develop a strategic business relationship, including Merdury's potential investment and participation in the completion of a Phase 3 clinical trial of the Company's VELDONA® drug candidate for treatment of oral warts in HIV-seropositive patients. On March 21, 2023, the Company announced that it had signed a distribution agreement with Topmed International Biotech Co., Ltd. ("Topmed"), a Taiwanese biotech company. Under the agreement, Topmed will be the exclusive distributor of pet supplements for cats and dogs based on Ainos' low-dose oral interferon-alpha formulation, VELDONA® in Taiwan. About Ainos, Inc. Headquartered in San Diego, California, Ainos, Inc. is a diversified medtech company engaged in developing innovative medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications. In addition to its proprietary therapeutics using low-dose non-injectable interferon, Ainos has also expanded its product portfolio to include Volatile Organic Compounds (VOC) and COVID-19 POCTs. To learn more, visit . Follow Ainos on Twitter (@AinosInc) and LinkedIn to stay up-to-date. Forward-Looking Statements This press release contains "forward-looking statements" about Ainos within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict," "project," "target," "future," "likely," "strategy," "foresee," "may," "guidance," "potential," "outlook," "forecast," "should," "will" or other similar words or phrases. Similarly, statements that describe the Company's objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements are based only on the Company's current beliefs, expectations, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. The Company's actual results may differ materially from those indicated in the forward-looking statements. Important factors that could cause the Company's actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release include, among others, the cost of production and sales potential of the planned drug treatments announced in this press release; the Company's dependence on revenues from the sale of COVID-19 test kits; the Company's limited cash and history of losses; the Company's ability to achieve profitability; the Company's ability to raise additional capital to continue the Company's product development; the ability to accurately predict the future operating results of the Company; the ability to advance Ainos' current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates the Company develops; the ability to obtain and maintain regulatory approval of Ainos product candidates; delays in completing the development and commercialization of the Company's current and future product candidates, which could result in increased costs to the Company, delay or limit the ability to generate revenue and adversely affect the business, financial condition, results of operations and prospects of the Company; intense competition and rapidly advancing technology in the Company's industry that may outpace its technology; customer demand for the products and services the Company develops; the impact of competitive or alternative products, technologies and pricing; disruption in research and development facilities; lawsuits and other claims by third parties or investigations by various regulatory agencies governing the Company's operations; potential cybersecurity attacks; increased requirements and costs related to cybersecurity; the Company's ability to realize the benefits of third party licensing agreements; the Company's ability to obtain and maintain intellectual property protection for Ainos product candidates; compliance with applicable laws, regulations and tariffs; continued listing on and compliance with the Nasdaq Capital Market; and the Company's success in managing the growth. A more complete description of these risk factors and others will be included in the "Risk Factors" section of Ainos' Annual Report on Form 10-K and other reports to be filed with the U.S. Securities and Exchange Commission, many of which risks are beyond the Company's control. In addition to the risks described above and in the Company's reports filed with the Securities and Exchange Commission, and press releases, other unknown or unpredictable factors also could cause actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release. The forward-looking statements made in this press release are expressly qualified in their entirety by the foregoing cautionary statements. Ainos undertakes no obligation to, and expressly disclaims any such obligation to, publicly update or revise any forward-looking statement to reflect changed assumptions, the occurrence of anticipated or unanticipated events or changes to the future results over time or otherwise, except as required by law. Investor Relations Contact ICR, LLC Robin Yang Tel: +1 646-224-6971 Email: Ainos.IR@icrinc.com Ainos, Inc. Condensed Consolidated Statements of Operations (Unaudited) Three months ended March 31 2023 2022 Revenues 49,164 87,200 Cost of revenues (100,848 ) (41,078 ) Gross (loss) profits (51,684 ) 46,122 Operating expenses: Research and development expenses 1,698,883 1,577,454 Selling, General and administrative expenses 762,465 551,730 Total operating expenses 2,461,348 2,129,184 Operating loss (2,513,032 ) (2,083,062 ) Non-operating income (expenses),net Interest expenses, net (9,273 ) (16,687 ) Other income (expenses), net 1,830 (146 ) Total non-operating income(expenses),net (7,443 ) (16,833 ) Net loss (2,520,475 ) (2,099,895 ) Net loss per common shares-basic and diluted (0.13 ) (0.22 ) Weighted average common shares outstanding- basic and diluted 20,011,602 9,625,133 Ainos, Inc. Condensed Consolidated Balance Sheets (Unaudited) March 31, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents 1,146,132 1,853,362 Accounts receivable, including related parties 111,283 201,546 Inventory, net 572,390 595,222 Other receivables - related parties 1,500,000 - Other current assets 303,318 195,787 Total current assets 3,633,123 2,845,917 Intangible assets, net 31,691,698 32,806,738 Property and equipment, net 1,314,605 1,375,676 Other Assets 68,817 80,683 Total assets 36,708,243 37,109,014 Liabilities and Stockholders' Equity Current liabilities: Convertible notes payable - related party 376,526 376,526 Notes payable, including related parties 684,000 884,000 Accrued expenses and others current liabilities 806,017 1,212,386 Total current liabilities 1,866,543 2,472,912 Long term liabilities: Convertible Note payable-non-current 2,500,000 - Operating lease liabilities-non-current 3,276 8,096 Total liabilities 4,369,819 2,481,008 Stockholders' equity Preferred stock, $0.01 par value; 10,000,000 shares authorized; none issued - - Common stock, $0.01 par value; 300,000,000 shares authorized as of March 31, 2023 and December 31,2022; 20,011,602 shares issued and outstanding as of March 31, 2023 and December 31, 2022 200,116 200,116 Additional paid-in capital 58,965,981 58,745,149 Accumulated deficit (26,636,081 ) (24,115,606 ) Translation adjustment (191,592 ) (201,653 ) Total stockholders' equity 32,338,424 34,628,006 Total liabilities and stockholders' equity 36,708,243 37,109,014 SOURCE: Ainos, Inc. View source version on accesswire.com:

Revenues increased by 3,832% year over year Debt ratio improved to 7% from 75% at year-end 2021 SAN DIEGO, CA / ACCESSWIRE / March 31, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 Financial Highlights Revenues were US$1,038,025 in the fourth quarter of 2022, up 3,832% year over year. Gross profit was US$459,815, up 2,668% year over year, representing a gross margin of 44.3% in the fourth quarter of 2022. Chun-Hsien Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "We delivered continued revenue growth in the fourth quarter and full year of 2022. At the same time, we made important progress in unlocking the potential of our key VOC POCT and VELDONA® technologies. We recently signed two memoranda of understanding (MoU) to further develop our VELDONA® formulation. Our MoU with Tah-An Chemical & Pharmaceutical Co., Ltd, a leading Taiwanese animal drug manufacturer, involves exploring the feasibility of manufacturing an animal investigational new drug based on our VELDONA® formulation. Our MoU with Merdury Biopharmaceutical Corp., a publicly-listed Taiwanese biopharma company, will focus on developing a strategic business relationship and collaboration on a Phase 3 Study of a VELDONA® drug candidate for treatment of oral warts in HIV-seropositive patients. Furthermore, we reached an agreement with Topmed International Biotech Co., Ltd. for exclusive distribution of our VELDONA® animal health supplements in Taiwan. We continue to forge ahead with our strategy of diversifying and expanding our revenue streams by monetizing our product portfolio and leveraging our intellectual property patents. To this end, our strategic priorities in 2023 include commercialization of our lead VOC POCT candidate, Ainos Flora, powered by our AI Nose platform, and exploration of further out-licensing opportunities for our VELDONA® candidates. Going forward, we will continue to advance and develop our innovative technologies while delivering long-term growth to our shareholders." Hui-Lan Wu, Chief Financial Officer of Ainos, commented, "Strong sales of our COVID-19 antigen self-test kits in Taiwan drove year-over-year topline growth of 3,832.1%. Recently, we further strengthened our financial position with a US$3 million convertible notes private placement. This transaction provides us with additional capital and flexibility as we continue to ramp up development and monetization of our portfolio while delivering on our long-term growth strategy." Fourth Quarter 2022 Financial Results Revenues Revenues increased by 3,832% to US$1,038,025 in the fourth quarter of 2022, from US$26,399 in the same period of 2021, driven by increased sales of the Company's COVID-19 Antigen Self-Test Kits in Taiwan. Cost of Revenues Cost of revenues was US$578,210 in the fourth quarter of 2022, compared with US$9,786 in the same period of 2021. The increase was primarily attributable to increased business activity relating to the Company's COVID-19 antigen self-test kits. Gross Profit In the fourth quarter of 2022, gross profit was US$459,815, representing a 44.3% gross margin, compared to US$16,613, or a 62.9% gross margin a year ago. The change in gross margin was driven by a shift in the Company's revenue mix. Total Operating Expenses Total operating expenses increased to US$2,586,399 in the fourth quarter of 2022 from US$1,452,041 in the same period of 2021. The increase was mainly attributable to depreciation and amortization expenses and share-based compensation. Operating expenses, excluding depreciation and amortization expenses and share-based compensation, were US$1,125,046 in the fourth quarter of 2022 as compared to US$782,930 a year ago. R&D expenses increased to US$1,798,868 in the fourth quarter of 2022 from US$1,273,847 a year ago. When excluding depreciation and amortization expenses, R&D expenses increased to US$586,224 from US$428,635 over the same period. SG&A expenses increased to US$787,531 from US$178,194 over the same period. When excluding depreciation and amortization expenses and share-based compensation, SG&A expenses increased to US$538,822 from US$354,295 over the same period. Net Loss Net loss attributable to common stock shareholders was US$2,131,008 in the fourth quarter of 2022, compared with US$1,444,770 in the same period of 2021. Full Year 2022 Financial Results Revenues Revenues increased by 492% to US$3,519,627 from US$594,563 in the full year of 2021, driven by increased sales of the Company's COVID-19 Antigen Self-Test Kits in Taiwan. Cost of Revenues Cost of revenues was US$2,114,284 in the full year of 2022, compared with US$184,181 in the same period of 2021. The increase was primarily attributable to increased business activity relating to the Company's test kits. Gross Profit In the full year of 2022, gross profit was US$1,405,343, representing a 40.0% gross margin, compared to US$410,382, or a 69.0% gross margin in the same period of 2021. The change in gross margin was driven by a shift in the Company's revenue mix. Total Operating Expenses Total operating expenses increased to US$15,381,555 in the full year of 2022 from US$4,277,808 in the same period of 2021. The increase was mainly attributable to depreciation and amortization expenses and share-based compensation. Operating expenses excluding depreciation and amortization expenses and share-based compensation were US$4,196,981 in the full year of 2022, as compared to US$2,060,517 in the full year of 2021. R&D expenses increased to US$6,845,964 in the full year of 2022 from US$1,920,645 in the same period of 2021. When excluding depreciation and amortization expenses, R&D expenses increased to US$2,134,935 from US$655,706 over the same period. SG&A expenses increased to US$8,535,591 from US$2,357,163 over the same period. When excluding depreciation and amortization expenses and share-based compensation, SG&A expenses increased to US$2,062,046 from US$1,404,811 over the same period. Net Loss Net loss attributable to common stock shareholders was US$14,006,690 in 2022, compared with US$3,888,661 in 2021. Balance Sheet As of December 31, 2022, the Company had cash and cash equivalents of US$1,853,362 compared with US$1,751,499 as of December 31, 2021. On March 13, 2023, the Company announced that it had entered into two convertible note purchase agreements, under which the Company issued and sold two convertible promissory notes in a principal amount of US$3 million to certain investors. Recent Developments On November 3, 2022, the Company announced that it is pursuing out-licensing opportunities for five new drug candidates for its low-dose oral interferon-alpha formulation, VELDONA®. Ainos has completed Phase 2 trials for the five new drug candidates and will work with potential partners to accelerate the candidates to Phase 3 trials and eventual commercialization of VELDONA®. On November 21, 2022, the Company announced that it had published preclinical data demonstrating the potential of its low-dose oral interferon-alpha formulation, VELDONA®, as treatment candidates for the two most common medical conditions for dogs and cats. On January 23, 2023, the Company announced that it had signed a Memorandum of Understanding with Taiwanese animal drug manufacturer Tah-An Chemical & Pharmaceutical Co., Ltd. to jointly explore the feasibility of manufacturing an animal investigational new drug based on the VELDONA® formulation. On March 14, 2023 the Company announced that it had signed a Memorandum of Understanding with Merdury Biopharmaceutical Corp., a Taipei Exchange Emerging Stock Board listed company, to jointly explore and develop a strategic business relationship, including Merdury's potential investment and participation in the completion of a Phase 3 clinical trial of the Company's VELDONA® drug candidate for treatment of oral warts in HIV-seropositive patients. On March 21, 2023, the Company announced that it had signed a distribution agreement with Topmed International Biotech Co., Ltd. ("Topmed"), a Taiwanese biotech company. Under the Agreement, Topmed will be the exclusive distributor of pet supplements for cats and dogs based on Ainos' low-dose oral interferon-alpha formulation, VELDONA® in Taiwan. About Ainos, Inc. Headquartered in San Diego, California, Ainos, Inc. is a diversified medtech company engaged in developing innovative medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications. In addition to its proprietary therapeutics using low-dose non-injectable interferon, Ainos has also expanded its product portfolio to include Volatile Organic Compounds (VOC) and COVID-19 POCTs. To learn more, visit: . Forward-Looking Statements This press release contains "forward-looking statements" about Ainos within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict," "project," "target," "future," "likely," "strategy," "foresee," "may," "guidance," "potential," "outlook," "forecast," "should," "will" or other similar words or phrases. Similarly, statements that describe the Company's objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements are based only on the Company's current beliefs, expectations, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. The Company's actual results may differ materially from those indicated in the forward-looking statements. Important factors that could cause the Company's actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release include, among others, the cost of production and sales potential of the planned drug treatments announced in this press release; the Company's dependence on revenues from the sale of COVID-19 test kits; the Company's limited cash and history of losses; the Company's ability to achieve profitability; the Company's ability to raise additional capital to continue the Company's product development; the ability to accurately predict the future operating results of the Company; the ability to advance Ainos' current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates the Company develops; the ability to obtain and maintain regulatory approval of Ainos product candidates; delays in completing the development and commercialization of the Company's current and future product candidates, which could result in increased costs to the Company, delay or limit the ability to generate revenue and adversely affect the business, financial condition, results of operations and prospects of the Company; intense competition and rapidly advancing technology in the Company's industry that may outpace its technology; customer demand for the products and services the Company develops; the impact of competitive or alternative products, technologies and pricing; disruption in research and development facilities; lawsuits and other claims by third parties or investigations by various regulatory agencies governing the Company's operations; potential cybersecurity attacks; increased requirements and costs related to cybersecurity; the Company's ability to realize the benefits of third party licensing agreements; the Company's ability to obtain and maintain intellectual property protection for Ainos product candidates; compliance with applicable laws, regulations and tariffs; continued listing on and compliance with the Nasdaq Capital Market; and the Company's success in managing the growth. A more complete description of these risk factors and others will be included in the "Risk Factors" section of Ainos' Annual Report on Form 10-K and other reports to be filed with the U.S. Securities and Exchange Commission, many of which risks are beyond the Company's control. In addition to the risks described above and in the Company's upcoming Form 10-K, other unknown or unpredictable factors also could cause actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release. The forward-looking statements made in this press release are expressly qualified in their entirety by the foregoing cautionary statements. Ainos undertakes no obligation to, and expressly disclaims any such obligation to, publicly update or revise any forward-looking statement to reflect changed assumptions, the occurrence of anticipated or unanticipated events or changes to the future results over time or otherwise, except as required by law. Investor Relations Contact ICR, LLC Robin Yang Tel: +1 646-224-6971 Email: Ainos.IR@icrinc.com Ainos, Inc. Condensed Consolidated Statements of Operations Three months ended December 31 Twelve months ended December 31 2022 2021 2022 2021 Revenues $ 1,038,025 $ 26,399 $ 3,519,627 $ 594,563 Cost of revenues (578,210) (9,786) (2,114,284) (184,181) Gross Profit 459,815 16,613 1,405,343 410,382 Operating expenses: Research and development expenses 1,798,868 1,273,847 6,845,964 1,920,645 Selling, General and administrative expenses 787,531 178,194 8,535,591 2,357,163 Total operating expenses 2,586,399 1,452,041 15,381,555 4,277,808 Operating loss (2,126,584) (1,435,428) (13,976,212) (3,867,426) Non-operating income and expenses, net Interest expenses, net (8,224) (9,328) (53,528) (18,689) Other income (losses), net 3,800 (15) 23,050 (2,547) Total non-operating income and expenses, net (4,424) (9,343) (30,478) (21,236) Net loss (2,131,008) (1,444,770) (14,006,690) (3,888,661) Net loss per common shares-basic and diluted $ (0.11) $ (0.15) $ (1.03) $ (0.51) Weighted average common shares outstanding- basic and diluted 19,866,674 9,501,762 13,637,292 7,551,360 Ainos, Inc. Condensed Consolidated Balance Sheets (Unaudited) December 31, 2022 December 31, 2021 Assets Current assets: Cash and cash equivalents $ 1,853,362 $ 1,751,499 Accounts receivable 201,546 - Inventory 595,222 - Other current assets 195,787 466,198 Total current assets 2,845,917 2,217,697 Intangible assets, net 32,806,738 37,329,191 Property and equipment, net 1,375,676 1,187,702 Other Assets 80,683 87,571 Total assets $ 37,109,014 $ 40,822,161 Liabilities and Stockholders' Equity Current liabilities: Convertible notes payable 376,526 3,376,526 Notes payable 884,000 213,405 Accrued expenses and others current liabilities 1,212,386 1,004,868 Payable -related party - 26,000,000 Total current liabilities 2,472,912 30,594,799 Long term liabilities: Operating lease liabilities-non-current 8,096 30,255 Total liabilities 2,481,008 30,625,054 Stockholders' equity Preferred stock, $0.01 par value; 10,000,000 shares authorized; none issued - - Common stock, $0.01 par value; 300,000,000 shares authorized as of Dec 31, 2022 and December 31,2021; 20,011,602 shares and 9,625,133 shares issued and outstanding as of Dec 31, 2022 and December 31, 2021 200,116 96,251 Additional paid-in capital 58,745,149 20,203,972 Accumulated deficit (24,115,606) (10,108,916) Translation adjustment (201,653) 5,800 Total stockholders' equity 34,628,006 10,197,107 Total liabilities and stockholders' equity $ 37,109,014 $ 40,822,161 SOURCE: Ainos, Inc. View source version on accesswire.com: